Ronald Levy
- Immunology top 0.01%
- Immunotherapy and Immune Responses 140
- Immune Cell Function and Interaction 85
- T-cell and B-cell Immunology 60
- Genetics top 0.02%
- Chronic Lymphocytic Leukemia Research 99
- Pathology and Forensic Medicine top 0.01%
- Lymphoma Diagnosis and Treatment 201
- Oncology top 0.05%
- CAR-T cell therapy research 123
- Radiology, Nuclear Medicine and Imaging top 0.01%
- Monoclonal and Polyclonal Antibodies Research 235
-
- Glycosylation and Glycoproteins Research 68
Ronald Levy
672 papers receiving 42.5k citations
Hit Papers
Peers
Comparison fields: 5 of 190
- Immunology 20.4k
- Genetics 8.4k
- Pathology and Forensic Medicine 12.8k
- Oncology 14.4k
- Radiology, Nuclear Medicine and Imaging 11.8k
Countries citing papers authored by Ronald Levy
This map shows the geographic impact of Ronald Levy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ronald Levy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ronald Levy more than expected).
Fields of papers citing papers by Ronald Levy
This network shows the impact of papers produced by Ronald Levy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ronald Levy. The network helps show where Ronald Levy may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Ronald Levy, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2023 | 3 | |
| 3 | 2022 | 27 | |
| 4 | 2021 | 16 | |
| 5 | 2020 | 58 | |
| 6 | 2020 | 45 | |
| 7 | 2019 | 82 | |
| 8 | 2019 | 91 | |
| 9 | 2018 | 142 | |
| 10 | 2018 | 181 | |
| 11 | 2017 | 76 | |
| 12 | Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibodybreakdown → | 2016 | 281 |
| 13 | Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITKbreakdown → | 2015 | 352 |
| 14 | 2015 | 67 | |
| 15 | 2013 | 229 | |
| 16 | 2012 | 19 | |
| 17 | 2010 | 398 | |
| 18 | 2008 | 73 | |
| 19 | Heavy-Charged-Particle Radiosurgery: Rationale and Method | 1993 | 2 |
| 20 | 1985 | 105 |
About Ronald Levy
Ronald Levy is a scholar working on Immunology, Pathology and Forensic Medicine, Radiology, Nuclear Medicine and Imaging, Genetics and Oncology, having authored 694 papers that have together received 44.9k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (235 papers), Lymphoma Diagnosis and Treatment (201 papers), Immunotherapy and Immune Responses (140 papers), CAR-T cell therapy research (123 papers), Chronic Lymphocytic Leukemia Research (99 papers), Immune Cell Function and Interaction (85 papers), Glycosylation and Glycoproteins Research (68 papers) and T-cell and B-cell Immunology (60 papers). The work is most often cited by research in Immunology (20.4k citations), Genetics (8.4k citations), Pathology and Forensic Medicine (12.8k citations), Oncology (14.4k citations) and Radiology, Nuclear Medicine and Imaging (11.8k citations). Ronald Levy has collaborated with scholars based in United States, France and Israel. Frequent co-authors include Debra K. Czerwinski, Wen‐Kai Weng, Izidore S. Lossos, Shoshana Levy, Roger A. Warnke, L A Lampson, Ash A. Alizadeh, David G. Maloney, DG Maloney and John M. Timmerman. Their work appears in journals such as Blood, The Journal of Immunology, Journal of Clinical Oncology, Proceedings of the National Academy of Sciences and New England Journal of Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.